🇺🇸 FDA
Patent

US 10240152

Compositions and methods for inhibiting expression of transthyretin

granted A61KA61K31/713A61K9/0019

Quick answer

US patent 10240152 (Compositions and methods for inhibiting expression of transthyretin) held by Alnylam Pharmaceuticals, Inc. expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
53
CPC classes
A61K, A61K31/713, A61K9/0019, A61P, A61P1/00